Medical Oncology

, 33:103 | Cite as

CA19-9-related tumor kinetics after first-line chemotherapy of patients with advanced pancreatic cancer: a monoinstitutional experience

  • Giuseppe CollocaEmail author
  • Antonella Venturino
  • Domenico Guarneri
Original Paper


The absolute value of carbohydrate antigen 19-9 (CA19-9) pretreatment and its reduction after chemotherapy are established prognostic variables for patients with advanced pancreatic cancer. The present study is a retrospective monoinstitutional evaluation of the prognostic role of the CA19-9 reduction and some CA19-9-related tumor kinetics parameters, such as tumor growth rate constant (G), kinetic tumor response and log ratio. Forty-one cases met the selection criteria. After 8 weeks only G reported an inverse relationship with OS (r = −0.494) that was confirmed by regression analysis (R 2 = 0.192). G after 8 weeks of chemotherapy appears as a possible surrogate end point of overall survival.


Pancreatic cancer CA19-9 Chemotherapy Serologic response Tumor growth rate 


Compliance with ethical standards

Conflict of interest


Ethical approval

For this type of study, formal consent is not required.


  1. 1.
    Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.CrossRefPubMedGoogle Scholar
  2. 2.
    Kaur S, Baine MJ, Jain M, Sasson AR, Batra SK. Early diagnosis of pancreatic cancer: challenges and new developments. Biomark Med. 2012;6:597–612.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2014. Ann Oncol. 2014;25:1650–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Koprowski H, Herlyn M, Steplewski Z, Sears HF. Specific antigen in serum of patients with colon carcinoma. Science. 1981;212:53–5.CrossRefPubMedGoogle Scholar
  5. 5.
    Ballehaninna UK, Chamberlain RS. Serum CA 19-9 as a biomarker for pancreatic cancer—a comprehensive review. Indian J Surg Oncol. 2011;2(2):88–100.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefPubMedGoogle Scholar
  7. 7.
    Bauer TM, El-Rayes BF, Li X, Hammad N, Philip PA, Shields AF, et al. Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy. Cancer. 2013;119:285–92.CrossRefPubMedGoogle Scholar
  8. 8.
    Mehrara E, Forssell-Aronsson E, Ahlman H, Bernhardt P. Specific growth rate versus doubling time for quantitative characterization of tumor growth rate. Cancer Res. 2007;67:3970–5.CrossRefPubMedGoogle Scholar
  9. 9.
    Mehrara E, Forssell-Aronsson E, Bernhardt P. Objective assessment of tumor response to therapy based on tumor growth kinetics. Br J Cancer. 2011;105:682–6.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Stein WD, Gulley JL, Schlom J, Madan RA, Dahut W, Figg WD, et al. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res. 2011;17(4):907–17.CrossRefPubMedGoogle Scholar
  11. 11.
    Karrison TG, Maitland ML, Stadler WM, Ratain MJ. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non-small-cell lung cancer. J Nat Cancer Inst. 2007;99:1455–61.CrossRefPubMedGoogle Scholar
  12. 12.
    Haas M, Heinemann V, Kullmann F, Laubender RP, Klose C, Bruns CJ, et al. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. J Cancer Res Clin Oncol. 2013;139:681–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Mehrara E, Forssell-Aronsson E, Ahlman H, Bernhardt P. Quantitative analysis of tumor growth rate and changes in tumor marker level: specific growth rate versus doubling time. Acta Oncol. 2009;48:591–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Furukawa H, Iwata R, Moriyama N. Growth rate of pancreatic adenocarcinoma: initial clinical experience. Pancreas. 2001;22(4):366–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Louzon Y, Xue C, Lesinski GB, Friedman A. A mathematical model for pancreatic cancer growth and treatments. J Theor Biol. 2014;351:74–82.CrossRefGoogle Scholar
  16. 16.
    Boeck S, Stieber P, Holdenrieder S, Wilkowski R, Heinemann V. Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology. 2006;70:255–64.CrossRefPubMedGoogle Scholar
  17. 17.
    He M, Wu C, Xu J, Guo H, Yang H, Zhang X, et al. A genome wide association study of genetic loci that influence tumor biomarkers cancer antigen 19-9, carcinoembryonic antigen and α fetoprotein and their associations with cancer risk. Gut. 2014;63:143–51.CrossRefPubMedGoogle Scholar
  18. 18.
    Rothenberg ML, Abbruzzese JL, Moore M, Portenoy RK, Robertson JM, Wanebo HJ. A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. Cancer. 1996;78(3 suppl):627–32.CrossRefPubMedGoogle Scholar
  19. 19.
    Brambs HJ, Claussen CD. Pancreatic and ampullary carcinoma. Ultrasound, computed tomography, magnetic resonance imaging and angiography. Endoscopy. 1993;25:58–68.CrossRefPubMedGoogle Scholar
  20. 20.
    Bonnetain F, Bonsing B, Conroy T, Dousseau A, Glimelius B, Haustermans K, et al. Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials). Eur J Cancer. 2014;50(17):2983–93.CrossRefPubMedGoogle Scholar
  21. 21.
    Kanda M, Fujii T, Takami H, Suenaga M, Inokawa Y, Yamada S, et al. The combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients. Surg Today. 2014;44(9):1692–701.CrossRefPubMedGoogle Scholar
  22. 22.
    Reitz D, Gerger A, Seidel J, Kornprat P, Samonigg H, Stotz M, et al. Combination of tumour markers CEA and CA 19-9 improves the prognostic prediction in patients with pancreatic cancer. J Clin Pathol. 2015;68(6):427–33.CrossRefPubMedGoogle Scholar
  23. 23.
    Hamada T, Nakai Y, Yasunaga H, Isayama H, Matsui H, Takahara N, et al. Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy. Br J Cancer. 2014;110:1943–9.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Pelzer U, Hilbig A, Sinn M, Stieler J, Bahra M, Dorken B, et al. Value of carbohydrate antigen 19-9 in predicting response and therapy control in patients with metastatic pancreatic cancer undergoing first-line therapy. Front Oncol. 2013;3:155.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Hammad N, Heilbrun LK, Philip PA, Shields F, Zalupski MM, Venkatramanamoorthy R, et al. CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy. Asia Pac J Clin Oncol. 2010;6:98–105.CrossRefPubMedGoogle Scholar
  26. 26.
    Maisey NR, Norman AR, Hill A, Massey A, Oates J, Cunningham D. CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer. 2005;93:740–3.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Saad ED, Machado MC, Wajsbrot D, Abramoff R, Hoff PM, Tabacof J, et al. Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine. Int J Gastrointest Cancer. 2002;32:35–41.CrossRefPubMedGoogle Scholar
  28. 28.
    Reni M, Cereda S, Balzano G, Passoni P, Rognone A, Fugazza C, et al. Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer. 2009;115:2630–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Hess V, Glimelius B, Grawe P, Dietrich D, Bodoky G, Ruhstaller T, et al. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol. 2008;9:132–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Wasan HS, Springett GM, Chodkiewicz C, Wong R, Maurel J, Barone C, et al. CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone. Br J Cancer. 2009;101:1162–7.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Gogas H, Lofts FJ, Evans TR, Daryanani S, Mansi JL. Are serial measurements of CA19-9 useful in predicting response to chemotherapy in patients with inoperable adenocarcinoma of the pancreas? Br J Cancer. 1998;77:325–8.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Halm U, Schumann T, Schiefke I, Witzigmann H, Mossner J, Keim V. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer. 2000;82:1013–6.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Stemmler J, Stieber P, Szymala AM, Schalhorn A, Schermuly MM, Wilkowski R, et al. Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin? Onkologie. 2003;26:462–7.PubMedGoogle Scholar
  34. 34.
    Ziske C, Schlie C, Gorschluter M, Mey U, Strehl J, Sauerbruch T, et al. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer. 2003;89:1413–7.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer. 2005;93:195–9.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Boeck S, Haas M, Laubender RP, Kullmann F, Klose C, Bruns CJ, et al. Application of a time-varying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer. Clin Cancer Res. 2010;16(3):986–94.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Department of OncologyG. Borea HospitalSanremo, ImperiaItaly

Personalised recommendations